Loading...
Market
What will be the leadership status at Jnana Therapeutics by December 31, 2024?
2
Resolution / Starting Odds
Joanne Kotz remains CEO • 25%
New CEO appointed from Otsuka • 25%
New CEO appointed externally • 25%
Other leadership changes • 25%
Official press release from Jnana Therapeutics or Otsuka Pharmaceutical
Story
Otsuka to Acquire Jnana Therapeutics for $1.1 Billion, $800M Upfront
Aug 1, 2024, 08:45 AM
Japan's Otsuka Pharmaceutical has announced an agreement to acquire U.S.-based Jnana Therapeutics for up to $1.1 billion. The deal includes an upfront payment of $800 million and up to $325 million in milestone payments. Jnana, a Boston-based clinical-stage biotech company, is known for its RAPID platform and the JNT-517 oral investigational drug, which has shown effectiveness for phenylketonuria (PKU) in Phase 1b/2 trials. Upon completion of the acquisition, Jnana will operate as a subsidiary of Otsuka in Boston and continue its research and development efforts, including work on autoimmune diseases. The company is led by CEO and co-founder Joanne Kotz. This acquisition adds to the recent uptick in private biotech mergers and acquisitions.
View original story
Similar markets
Joanne Kotz remains CEO • 25%
New CEO appointed from Jnana's current team • 25%
New CEO appointed from Otsuka • 25%
Other • 25%
CEO replaced • 25%
CFO replaced • 25%
Both CEO and CFO replaced • 25%
No changes in executive leadership • 25%
FDA approval of JNT-517 • 25%
Initiation of Phase 3 trials for JNT-517 • 25%
New drug discovery announcement • 25%
Other • 25%
CEO steps down • 25%
CFO steps down • 25%
Both step down • 25%
No change • 25%
Significant advancements in PKU treatment • 25%
Significant advancements in autoimmune disease research • 25%
No significant advancements • 25%
Other • 25%
CEO change • 25%
CFO change • 25%
Both CEO and CFO change • 25%
No change • 25%
Anne Wojcicki remains CEO • 25%
New CEO appointed from internal candidate • 25%
New CEO appointed from external candidate • 25%
Interim CEO appointed • 25%
CEO steps down • 25%
CFO steps down • 25%
Both CEO and CFO step down • 25%
No significant leadership changes • 25%
Yes • 50%
No • 50%
CEO resignation • 25%
Other executive resignations • 25%
No changes • 25%
Board of Directors changes • 25%
New CEO appointed • 25%
New CTO appointed • 25%
New CFO appointed • 25%
No significant leadership changes • 25%
CEO replaced • 25%
CFO replaced • 25%
CTO replaced • 25%
No key executive changes • 25%